Icecure Medical (NASDAQ:ICCM) Stock, Quote.Headers.trade-ideas

Icecure Medical

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMCX

BIMI

BJDX

FLFV

ICCM

KAVL

LRHC

NDRA

NRIX

OVID

SCNI

SVMH

TRNR

VERO

XTLB

ZAPP

Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Earnings

Earnings Misses

Penny Stocks

Health Care

Analyst Ratings

General

The Oncology Institute, Inc. (NASDAQ: TOI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.

The Oncology Institute, Inc. Reports Q1 Loss, Lags Revenue Estimates

Screenshot 2024-04-26 at 8.22.23 AM

Biotech

New Standard of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy

Icecure Medical Ltd

Elon Musk, who has been very vocal about governments&#8217;<a href="https://www.benzinga.com/government/24/09/40971374/elon-musk-responds-to-venture-capitalists-claim-on-government-subsidies-for-spacex-tesla-do-some-res"> unfair treatment meted out to his business ventures, </a>vented out his frustration yet again on Monday.
What Happened: The trigger for another outburst by Musk came in the form of a post by a Tesla influencer from Canada, who noted that federal and provincial governments have reiterated support for Canadian satellite telecom company Telesat&#8217;s Lightspeed satellite network project.
The project was touted as a source of 967 additional jobs in Canada and Quebec and involved an investment of C$2.62 billion. This would translate to a public subsidy of just under C$3 million per job for a project that will cost a total of more than C$6 billion and aims to connect all Canadians to high-speed Internet by 2030,&#8221; the social-media user said on X. He contrasted that with Musk&#8217;s Starlink, which did not receive any subsidies but already had over 400,000 satisfied users in Canada.
Starlink is owned by SpaceX and it provides low-latency broadband internet service.
The Tesla influencer said Starlink could &#8220;provide all Canadians in rural and remote locations with reliable high-speed internet &#x2A;today&#x2A; and for a fraction of that cost.&#8221;
Musk jumped in and said competitors receive vastly more subsidies than SpaceX or Tesla. &#8220;The success of SpaceX/Tesla is in spite of competitor subsidies!&#8221; he said.
He also referred to the U.S. government&#8217;s giveaway for a North American Supercharger network to compete against Tesla, adding that it still failed. The billionaire could have referred to Charge Enterprises, which partnered with Stellantis and General Motors, filing for Chapter 11 bankruptcy earlier this year.
Despite massive subsidies to Starlink competitors for American rural broadband they failed, Musk said. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Competitors receive vastly more subsidies than SpaceX or Tesla. The success of SpaceX/Tesla is in spite of competitor subsidies! Look at how much was given away for a North American Supercharger network to compete against Tesla and it still failed. Or the massive subsidies… <a href="https://t.co/apLWr3pKGG">https://t.co/apLWr3pKGG</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1838238701886849183?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-invest-in-spacex">How To Invest In SpaceX</a>
Why It&#8217;s Important: The Tesla CEO clarified the same in an exchange with Sun Microsystems co-founder and venture capitalist Vinod Khosla over the weekend.
When the latter questioned how much government money SpaceX gets and whether Tesla could have survived without EV subsidies, Musk retorted sharply. &#8220;Do some research before you display your utter ignorance,&#8221; he said, adding that SpaceX gets no subsidies and received half as much as Boeing for astronaut transport, but did 100% of the work. He also clarified that government subsidies make up only a minor portion of his electric-vehicle manufacturing company Tesla's revenue.
Musk&#8217;s SpaceX is already on a warpath with the Federal Aviation Administration (FAA) over regulatory delays and safety concerns, particularly regarding its Starship development program. The regulator has maintained that its accent is on safety and environmental protection but Musk has been rooting for a more agile and forward-thinking regulatory approach that aligns with SpaceX's fast-paced innovation agenda.
Recently Rep.&nbsp;Kevin Kiley&nbsp;(R-Calif.) applauded Musk's SpaceX for its&nbsp;Polaris Dawn&nbsp;mission in a speech and also <a href="https://www.benzinga.com/government/24/09/40972034/elon-musk-responds-as-california-congressman-slams-bureaucratic-roadblocks-for-spacex-program-agenci">voiced concerns regarding the regulatory clampdown on the company. </a>&#8220;We continue to be stuck in the reality where it takes longer to do the government paperwork to license a rocket launch than it does to design and build the actual hardware,&#8221; Kiley said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40787779/spacex-launches-polaris-dawn-crew-to-space-with-aim-of-first-ever-private-spacewalk">SpaceX Launches Polaris Dawn Crew To Space With Aim Of First-Ever Private Spacewalk</a></li>
</ul>
Image via Shutterstock

Equities

Tech

Elon Musk Cries Foul Over Governments' Preferential Treatment For Rival Companies: 'Success Of SpaceX/Tesla Is In Spite Of Competitor Subsidies'

While debate around the U.S. government's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holdings continues and El Salvador's pioneering embrace hogs headlines, a small Himalayan nation nestled between India and China was quietly adding the top cryptocurrency to its reserves.
What happened: According to a report by Firstpost America, the landlocked South Asian held&nbsp; about 13,011 Bitcoin in its coffers, worth $821 million as of this writing. This made it the fourth-largest government holder of the apex digital currency behind the U.S., China, and UK, and surprisingly, above El Salvador.&nbsp;
With an estimated GDP of $3.11 billion as per <a href="https://www.statista.com/statistics/527240/gross-domestic-product-gdp-in-bhutan/">Statista</a>, Bitcoin holdings represented nearly one-third of Bhutan's economy.
However, <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36787705/silk-road-loot-goes-public-us-government-to-sell-off-132-5m-in-seized-bitcoin">unlike other nations</a>, Bhutan's holdings didn't come from law enforcement seizures, but from indigenously developed mining capability, backed by its abundant hydropower resources.
The report added that Bhutan's state-owned investment firm, Druk Holdings, maintains custody of all Bitcoins.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40994028/elon-musk-dons-his-maga-hat-to-meet-pro-bitcoin-president-javier-milei-duo-discuss-argenti">Elon Musk Dons His MAGA Hat To Meet Pro-Bitcoin President Javier Milei: Duo Discuss Argentina&#8217;s Journey To Normalcy</a>
These findings were amplified on X by none other than Michael Saylor, a well-known proponent of Bitcoin who, via his company MicroStrategy, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40899629/microstrategy-doubles-down-on-bitcoin-can-the-stock-sustain-its-rally">has spearheaded the corporate adoption</a> of the world's largest cryptocurrency.
"Bhutan is leading the way in global Bitcoin adoption," Saylor wrote.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I can't believe Bhutan skipped ahead of El Salvador. We need to STEP IT UP!!! <a href="https://t.co/1smaVzvjh5">https://t.co/1smaVzvjh5</a>
&mdash; Max Keiser (@maxkeiser) <a href="https://twitter.com/maxkeiser/status/1838283844283138256?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Furthermore, Max Keiser, senior Bitcoin adviser to El Salvador President Nayib Bukele, expressed astonishment at Bhutan surpassing the Central American nation in Bitcoin holdings, saying, &#8220;We need to STEP IT UP!!!&#8221;
Why It Matters: Recent months have seen a surge in discussions on the topic of holding Bitcoin in national reserves, with former President Donald Trump <a href="https://www.benzinga.com/top-stories/24/08/40372436/trump-criticizes-us-bitcoin-sales-calls-for-national-cryptocurrency-stockpile-if-we-dont-do-it-china">pitching in favor</a> of the idea during his campaign.
The narrative was strengthened when pro-cryptocurrency Senator Cynthia Lummis (R-Wyo.) proposed a bill to <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40087880/cynthia-lummis-unveils-strategic-bitcoin-reserve-legislation-this-is-our-louisiana-purchas">establish a U.S. strategic Bitcoin reserve</a>.
Price Action: At the time of writing, Bitcoin was exchanging hands at $63,122.89, down 1.06% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40993290/trump-vs-harris-2024-election-betting-odds-show-vice-president-maintains-lead-as-race-near">Trump Vs. Harris: 2024 Election Betting Odds Show Vice President Maintains Lead As Race Nears One-Month Mark</a></li>
</ul>
Photo courtesy: Flickr

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Max Keiser Says El Salvador 'Needs To Step It Up' As Bhutan's Bitcoin Adoption Astonishes Crypto Market

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) <a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">is reportedly considering a buyout</a> of Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), a move that could significantly diversify Qualcomm&#8217;s product offering. However, analysts are warning of potential challenges that could hinder the success of this acquisition.
What Happened: Qualcomm&#8217;s interest in acquiring Intel has been met with skepticism from analysts, <a href="https://www.businessinsider.com/qualcomm-considers-intel-buyout-analysts-see-major-hurdles-2024-9">reported</a> Business Insider. The potential deal, which could help Qualcomm expand, is seen as a risky move due to Intel&#8217;s struggling semiconductor manufacturing unit.
Intel&#8217;s shares have plummeted approximately 77% from their 52-week high, making the company an attractive target not just for Qualcomm but also for Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), which reportedly proposed to make an equity-like investment <a href="https://www.benzinga.com/markets/equities/24/09/40973740/intel-has-a-new-knight-in-shining-armor-after-qualcomm-apollo-global-management-reportedly-propo">of up to $5 billion in the company</a>.
However, Stacy Rasgon, a prominent chip analyst from Bernstein, expressed skepticism about the potential deal. &#8220;We would prefer that Qualcomm not pursue this as it seems very risky to us given uncertain returns,&#8221; Rasgon and his team wrote.
Qualcomm aims to diversify its revenue streams by entering the PC and data center markets, which Intel dominates. However, Intel&#8217;s semiconductor factories, or fabs, pose significant challenges. Rasgon noted that Intel has struggled to manage its fabs, allowing competitors like TSMC to gain an edge.
Rasgon also highlighted the political importance of Intel&#8217;s U.S.-based fabs in Arizona, Oregon, and New Mexico. He speculated that Qualcomm might sell these fabs if the acquisition goes through, but questioned whether Intel is desperate enough to consider such a move.
&#8220;Is Intel desperate enough to seriously consider something like this? We&#8217;re not so sure,&#8221; Rasgon and his team concluded.
Why It Matters: The potential acquisition of Intel by Qualcomm could face significant hurdles, according to analysts. The deal could reportedly <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40981806/qualcomms-potential-intel-buyout-could-face-antitrust-hurdles-analysts-reveal-intri">encounter rigorous antitrust scrutiny</a> globally, given that it would merge two major chip firms. This could create a giant with significant market shares in smartphones, PCs, and servers.
Benchmark analyst Cody Acree said the <a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">acquisition is &#8220;logically unlikely.</a>&#8221; According to Acree, Qualcomm would need to offer a compelling 40% to 50% premium over the current trading price of around $22 for shareholders to take the deal seriously. However, the regulatory scrutiny surrounding the transaction may be too difficult to overcome.
Meanwhile, Intel has been facing its own challenges, with CEO Pat Gelsinger presenting a <a href="https://www.benzinga.com/markets/equities/24/09/40673694/intel-ceo-pat-gelsinger-to-present-board-with-major-asset-sale-and-cost-cutting-plan-including-h">comprehensive plan to the board</a> in September. The plan focuses on asset sales and cost reductions, including halting a $32 billion project in Germany. 
If the Qualcomm-Intel deal goes through, it could result in one of the largest M&amp;A deals ever, surpassing Microsoft Corporation&#8217;s <a href="https://www.benzinga.com/general/gaming/23/10/35240972/microsofts-gaming-powerhouse-grows-activision-blizzard-bought-for-69-billion" target="_blank" rel="noreferrer noopener">$69 billion acquisition</a> of Activision Blizzard.
Price Action: Intel&#8217;s shares closed 3.3% higher on Monday at $22.56, while Qualcomm&#8217;s shares closed 1.75% lower at $165.96, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Image via Shutterstock

INTC

QCOM

Intel, Which Cratered Around 77% From Its 52-Week Peak, Finds A New Knight In Shining Armor As Qualcomm And Apollo Propose Buyout Deal, But This Analyst Thinks It Doesn't Make Sense: 'It Seems Very Risky To Us Given Uncertain Returns'

In the latest development, Taiwan has strongly denied China&#8217;s accusations of Taiwanese-backed cyberattacks, calling them baseless and part of a disinformation campaign.
What Happened: Taiwan&#8217;s government officials have dismissed China&#8217;s accusations of Taiwanese hacking as false on Tuesday, Reuters reported on Tuesday. Beijing had claimed a Taiwan military-backed group named &#8220;Anonymous64&#8221; was responsible for cyberattacks on Chinese targets.
China&#8217;s national security ministry made these allegations on Monday, urging citizens to report &#8220;anti-propaganda sabotage&#8221; and even published photos of three Taiwanese individuals they claimed were involved. Taiwan&#8217;s Defence Minister Wellington Koo responded by asserting that China is the primary source of global cyberattacks, targeting Taiwan and other democracies.
&#8220;China is the first country when it comes to daily cyber attacks, doing it against Taiwan and countries with similar democratic ideals. They are the real originators,&#8221; Koo stated. 
He further emphasized that China&#8217;s accusations are baseless and will not deter Taiwan&#8217;s military from its duties.
Premier Cho Jung-tai also addressed the issue, accusing China of spreading disinformation to undermine Taiwan. 
&#8220;We must respond forcefully to fake news accusations against us,&#8221; Cho said. Taiwan continues to reject China&#8217;s sovereignty claims, maintaining that only its people can determine the island&#8217;s future.
See Also: <a href="https://www.benzinga.com/news/24/09/40980997/china-tightens-export-rules-on-nuclear-biotech-and-missile-technologies-to-bolster-national-security?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">China Tightens Export Rules On Nuclear, Biotech And Missile Technologies To Bolster National Security Amid Global Tensions</a>
Why It Matters: The allegations from China come amid escalating tensions between the two nations. On Monday, Beijing&#8217;s top intelligence agency accused a<a href="https://www.benzinga.com/news/24/09/40978209/china-accuses-taiwan-backed-hacker-group-of-targeting-beijing-amid-deteriorating-cross-strait-relati"> group of Taiwanese hackers</a>, allegedly backed by Taipei&#8217;s defense ministry, of targeting websites in mainland China, Hong Kong, and Macau. The group, known as "Anonymous64," is described as a "cyber army" supported by Taiwan's Information, Communications and Electronic Force Command (ICEFCOM). These accusations were made as cross-strait relations continued to deteriorate, especially after Lai Ching-te assumed leadership in Taiwan in May. Lai is a member of the Democratic Progressive Party (DPP), which leans towards independence, a stance that Beijing strongly opposes.
Additionally, the U.S. and Taiwan have been strengthening their <a href="https://www.benzinga.com/news/24/09/40957200/amid-china-threat-us-and-taiwan-team-up-to-boost-drone-industry-cooperation-to-de-risk-supply-chains">cooperation to counteract</a> Chinese influence. In September, a delegation of U.S. drone and anti-drone companies visited Taipei to discuss creating supply chains independent of China. This collaboration aims to mitigate risks associated with Chinese products that have dual civilian and military uses. Taiwan&#8217;s Defence Minister Wellington Koo stated that this visit is an opportunity for Taiwan to integrate into U.S. supply chains and engage in co-production, helping Taiwan overcome export challenges due to its international status and pressure from China.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Global

Taiwan Claps Back After China Blames Taipei Backed Hackers For Cyberattacks: 'They Are The Real Originators'

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the S&amp;P 500 jumping to a new closing high.
All three major indices recorded weekly gains, with the S&amp;P 500 gaining around 1.4% and adding more than 19% in 2024. The Dow gained around 1.6% last week, while the tech-heavy Nasdaq jumped around 1.5% during the week.
On the economic data front, the S&amp;P Global manufacturing PMI declined to 47 in September from 47.9 in the prior month, versus market estimates of 48.5. The S&amp;P Global flash composite PMI slipped to 54.4 in September compared to 54.6 in August and versus market estimates of 54.3.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, consumer discretionary, and real estate stocks recording the biggest gains on Monday. However, healthcare and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 61 points to 42,124.65 on Monday. The S&amp;P 500 rose 0.28% to 5,718.57, while the Nasdaq Composite gained 0.14% at 17,974.27 during Monday's session.
Investors are awaiting earnings results from AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) and Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 64.4, the index remained in the &#8220;Greed&#8221; zone on Monday, versus a prior reading of 63.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financials Stocks That May Plunge In September</a></li>
</ul>

Long Ideas

RCAT

S&P Settles At Fresh Record High: Investor Sentiment Improves, But Fear Index Remains In 'Greed' Zone

South Korea has issued a stern warning of military action in response to Kim Jong Un&#8216;s North Korea recently launching trash-filled balloons.
What Happened: Incheon International Airport, one of Asia&#8217;s busiest, faced temporary shutdowns after a balloon was spotted nearby. Operations paused for 70 minutes before the balloon landed in the ocean. Shortly after resuming, debris was found, causing another brief halt, South China Morning Post <a href="https://scmp.com/week-asia/politics/article/3279661/south-korea-vows-military-response-norths-balloons-stoking-escalation-fears?module=top_story&amp;pgtype=homepage">reported</a> on Tuesday.
North Korean balloons have disrupted operations at Incheon and Gimpo airports five times in June and July, impacting 133 flights and 18,000 passengers, according to Seoul aviation authorities.
Since late May, North Korea has launched around 5,500 trash-filled balloons on 22 occasions, retaliating against anti-Pyongyang leaflets sent by South Korean defectors and activists. This month alone, 11 launches occurred, including about 120 balloons from Sunday evening to Monday morning.
South Korea&#8217;s Joint Chiefs of Staff condemned the North&#8217;s actions, stating that &#8220;stern military measures&#8221; would be taken if public safety is threatened. In response, South Korea resumed propaganda broadcasts along the border, which North Korea countered with its own broadcasts.
See Also: <a href="https://www.benzinga.com/news/24/09/40973164/nba-star-shaquille-oneal-threw-tim-walz-out-from-his-big-chicken-restaurant-and-said-dont-come-back?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">NBA Star Shaquille O&#8217;Neal Threw Tim Walz Out From His Big Chicken Restaurant And Said, &#8216;Don&#8217;t Come Back&#8217;</a>
Lee Il-woo from the Korea Defence Network suggested that South Korea could use small-caliber machine guns on helicopters to shoot down the balloons. Meanwhile, Shin Won-sik, South Korea&#8217;s top security official, warned that North Korea might escalate tensions further with a nuclear test.
Why It Matters: The balloon incidents have been escalating <a href="https://www.benzinga.com/news/24/05/39058090/south-korea-accuses-kim-jong-uns-north-korea-of-sending-balloons-filled-with-trash-and-excrement">since late May,</a> when South Korea accused North Korea of sending balloons filled with trash and excrement over the fortified border. The South Korean military had to deploy its explosives ordnance unit and chemical and biological warfare response team to inspect and collect the objects, urging residents to avoid and report any sightings.
In early June, North Korean defectors in Seoul retaliated by <a href="https://www.benzinga.com/news/24/06/39206733/after-kim-jong-un-pauses-trash-filled-balloons-north-korean-defectors-float-k-pop-balloons-over-bord">launching large balloons</a> filled with K-pop and South Korean cultural content across the border. This act was justified as a response to the trash-filled balloons sent by North Korea, which they considered an insult to the South Korean people.
Most recently, in late July, North Korea launched nearly <a href="https://www.benzinga.com/news/24/07/39950625/kim-jong-uns-north-korea-sent-nearly-500-trash-balloons-to-south-korea-in-last-24-hours-disrupting-f">500 trash-filled balloons</a> into South Korean airspace within a 24-hour period, causing flight disruptions and even a rooftop fire. This ongoing propaganda campaign by North Korea against defectors and activists in South Korea has led to multiple disruptions at Seoul's Gimpo and Incheon airports.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image by Kanchi1979 via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

South Korea Vows 'Stern Military Action' After Trash Balloons From Kim Jong Un's North Korea Disrupt Country's Busiest Airport

Takeda ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&amp;,%20esheet=54124287&amp;,%20newsitemid=20240918509211&amp;,%20lan=en-US&amp;,%20anchor=TSE%3A4502%2FNYSE%3ATAK&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">TAK</a>) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy.
The approval is based primarily on the results of the FRESCO-2 trial, a global Phase 3 clinical trial conducted in the United States, Europe, Japan and Australia. The trial compared FRUZAQLA plus best supportive care (BSC) with placebo plus BSC in patients with previously treated metastatic colorectal cancer (mCRC). The FRESCO-2 trial met all primary and key secondary efficacy endpoints and demonstrated consistent benefits in patients who received FRUZAQLA, regardless of the types of therapy the patients had previously received. FRUZAQLA demonstrated a manageable safety profile in the FRESCO-2 trial, with the incidence of adverse events leading to discontinuation being 21% in the placebo plus BSC arm compared to 20% in the FRUZAQLA plus BSC arm.1 The data from the FRESCO-2 trial were <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252823%252900772-9%2Fabstract&amp;esheet=54124287&amp;newsitemid=20240918509211&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=4ae4f0cb6c84175356b3a0226e262316">published</a> in The Lancet in June 2023.
Dr. Takayuki Yoshino, deputy director of hospital, head, Division for the Promotion of Drug and Diagnostic Development, and chief, Department of Gastrointestinal Oncology at the National Cancer Center Hospital East, who served on the FRESCO-2 study Steering Committee, said, "Although the mortality rate of colorectal cancer has been going down in recent years due to early screening and advances in treatment, the 5-year survival rate for metastatic colorectal cancer remains low and new treatment options are much in need. The approval of FRUZAQLA in Japan offers new hope for patients and families of patients with metastatic colorectal cancer, as well as for healthcare personnel involved in colorectal cancer treatment. I feel that it is of great clinical significance."
"For more than a decade, Takeda has been a leader in advancing the treatment of metastatic colorectal cancer in Japan. With this approval of FRUZAQLA, we are able to further support patients living with this debilitating disease," said Teresa Bitetti, president of the Global Oncology Business Unit at Takeda. "FRUZAQLA is now approved in the U.S., European Union, Japan and a number of other countries around the world, and we remain committed to bringing this treatment to additional patients with metastatic colorectal cancer around the world who urgently need new therapeutic options."

Government

Regulations

Takeda's FRUZAQLA Capsules Approved in Japan for Advanced Colorectal Cancer Treatment

Oportun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>), a mission-driven financial services company, today announced the closing of an amendment and extension to its long-term warehouse facility. Features of this facility include: &nbsp;
<ul>
<li>$306 million total commitment</li>
<li>Goldman Sachs as senior lender – and Jefferies, as mezzanine lender – both existing, longstanding lenders to Oportun</li>
<li>A new two-year revolving period</li>
<li>Collateralized by Oportun's unsecured and secured personal loan originations &nbsp;</li>
</ul>
"This warehouse facility extension expands on Oportun's longstanding lending relationships", said Jonathan Coblentz, Chief Financial Officer of Oportun. "With the support of our lenders at Goldman Sachs and Jefferies, this committed financing will help drive Oportun's responsible growth in the years ahead."
Oportun maintains a diverse set of capital sources including committed warehouse facilities, asset-backed securitizations, corporate-level debt financing, and whole loan sales.

OPRT

Reported Earlier, Oportun Secures $306M Financing Extension With Goldman Sachs and Jefferies

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects AutoZone, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) to report quarterly earnings at $53.53 per share on revenue of $6.22 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. AutoZone shares fell 0.7% to $3,027 in after-hours trading.</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) posted better-than-expected results for its first quarter on Monday. The company reported quarterly earnings of 85 cents which beat the analyst consensus estimate of 82 cents per share. AAR shares gained 3.4% to $71.44 in the after-hours trading session.</li>
<li>Analysts expect THOR Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) to post quarterly earnings at $1.30 per share on revenue of $2.47 million before the opening bell. THOR Industries shares gained 1.6% to $104.83 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) announced a $2 billion private placement of senior convertible notes. Snowflake shares fell 3.1% to $109.71 in the after-hours trading session.</li>
<li>Analysts are expecting KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) to post quarterly earnings at $2.06 per share on revenue of $1.73 billion. The company will release earnings after the closing bell. KB Home shares gained 1.1% to close at $88.20 on Monday.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financial Stocks That May Plunge In September</a></li>
</ul>
Photo courtesy: Shutterstock

SNOW

AutoZone, Thor Industries And 3 Stocks To Watch Heading Into Tuesday

Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) (the "Company" or "Excelerate"), a leading provider of floating storage and regasification units (FSRUs) and liquefied natural gas (LNG) solutions, and PetroVietnam Technical Services Corporation (PTSC), a subsidiary of Vietnam Oil and Gas Group (PetroVietnam) and the leading provider of oil &amp; gas and industrial services in Vietnam, have signed a strategic partnership agreement to jointly study FSRU based technical solutions for LNG imports into Vietnam.
Through this strategic alliance, Excelerate and PTSC will leverage their unique strengths and combined resources to deliver affordable and reliable energy solutions that address Vietnam's growing energy demands while supporting the country's transition to carbon neutrality.
Under the partnership agreement, the two companies will conduct joint feasibility studies to assess the viability of FSRU opportunities in Vietnam. The studies aim to optimize existing natural gas infrastructure and augment domestic supply with regasified LNG to help meet the growing demand for natural gas and stimulate the development of a regional gas market.

Reported Earlier, Excelerate Energy and PetroVietnam Partner To Boost Vietnam's LNG Imports

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.firstam.com&amp;esheet=54126266&amp;newsitemid=20240923810819&amp;lan=en-US&amp;anchor=First+American+Financial+Corporation&amp;index=1&amp;md5=70ff5a7d15f2af52f7e408adc440e753">First American Financial Corporation</a> (NYSE: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.firstam.com%2Finvestor&amp;esheet=54126266&amp;newsitemid=20240923810819&amp;lan=en-US&amp;anchor=FAF&amp;index=2&amp;md5=42d3b12043586201743f4291dde8c059">FAF</a>), a premier provider of title, settlement and risk solutions for real estate transactions, today announced the pricing of a public offering of $450 million of its 5.450 percent senior notes due 2034. The offering is expected to close on September 30, 2024, subject to customary conditions.
The notes will be general senior unsecured obligations of the company and will rank equally in right of payment with the company's existing and future senior unsecured indebtedness. Interest will be paid semi-annually on March 30 and September 30, beginning March 30, 2025. The company intends to use the net proceeds from the sale of the notes for repayment at maturity of the company's 4.60% senior notes due 2024 and for general corporate purposes, which may include, among other possible uses, acquisitions, funding for working capital, repurchase of the company's capital stock and other capital expenditures. The company may also use the net proceeds for temporary investments until it needs them for general corporate purposes.

Offerings

Reported Earlier, First American Financial Raised $450M Via Senior Notes Offering For Debt Repayment

Bank of America has identified crucial dates for the stock market leading up to the <a href="https://www.benzinga.com/markets/equities/24/09/40974512/stifel-warns-of-12-market-drop-by-end-of-2024-as-s-p-500-faces-high-valuations-and-speculative-r">November Presidential election</a>.
What Happened: In a note released on Monday, Bank of America highlighted several key dates. The bank used options prices to predict potential movements in the S&amp;P 500 index. The most significant date is Nov. 6, the day after the election, with an estimated 2.5% move in either direction, <a href="https://markets.businessinsider.com/news/stocks/stock-market-most-important-daysstock-market-between-now-and-election-2024-9">reported</a> Business Insider.
Other important dates include Oct. 4 and Nov. 1, when nonfarm payroll reports are released. These dates could see a 1% move in the S&amp;P 500. Oct. 21 is another critical date, marking the start of major tech companies&#8217; third-quarter earnings announcements.
Additionally, Oct. 10 is noted for the release of the September CPI data, though its impact is expected to be less significant compared to labor market data. The Federal Reserve&#8217;s recent interest rate cut has shifted focus from inflation to labor market indicators.
See Also: <a href="https://www.benzinga.com/news/24/09/40972893/trumps-mars-landing-promise-gets-slammed-by-peter-schiff-even-as-elon-musk-says-spacex-plans-5-launc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Mars Landing Promise Gets Slammed By Peter Schiff Even As Elon Musk Says SpaceX Plans 5 Launches To Red Planet In 2 Years</a>
Why It Matters: The stock market is on edge as it approaches the November election, with several analysts predicting significant volatility. 
Stifel recently warned of a <a href="https://www.benzinga.com/markets/equities/24/09/40974512/stifel-warns-of-12-market-drop-by-end-of-2024-as-s-p-500-faces-high-valuations-and-speculative-r">potential 12% market drop by the end of 2024</a>, citing high valuations and speculative risks. Chief equity strategist Barry Bannister pointed out that the S&amp;P 500 could experience a correction to the low 5,000s by the fourth quarter.
In early September, Tom Lee, a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40701071/market-bull-warns-of-up-to-10-september-pullback-urges-caution-but-stresses-be-read">prominent equity strategist</a>, anticipated a 7%-10% market pullback, urging caution but also advising investors to be ready to &#8220;buy that dip.&#8221; Lee noted that September has historically been the weakest month for stocks, with the S&amp;P 500 averaging a 0.7% loss every September since 1950.
Additionally, market strategist Jay Woods discussed the potential impacts of the election year and Federal Reserve rate cuts on the stock market. In an interview, Woods mentioned that the Fed&#8217;s expected rate cut in September comes as investors try to predict market movements <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40533318/exclusive-market-strategist-on-small-cap-rally-election-year-fed-cuts-and-whats-next-i">amid the 2024 presidential election</a>. Woods says the Fed was late to raise rates and has been late to cut rates.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40969619/trump-ally-sarah-huckabee-sanders-jabs-kamala-harris-for-not-having-biological-children-doesnt-have?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Ally Sarah Huckabee Sanders Jabs Kamala Harris For Not Having Biological Children: &#8220;Doesn&#8217;t Have Anything Keeping Her Humble!&#8221;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Key Stock Market Dates Predicting Major Swings Revealed Ahead Of 2024 Election, According To Bank Of America

Nova Minerals Limited ("Nova" and the "Company") (Nasdaq NVA, NVAWW) (ASX: NVA), (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NVAAF#OTC">NVAAF</a>)(FSE: QM3)), a gold and critical minerals exploration stage company focused on advancing the Estelle Gold Project in Alaska, U.S.A., today announced the pricing of an underwritten public offering of 430,000 American Depository Shares ("ADS"), with an ADS-to-ordinary-share ratio of 1 to 60, at a price to the public of $5.00 per ADS, for gross proceeds of $2,150,000, before deducting underwriting discounts and offering expenses. In addition, Nova has granted the underwriters a 45-day option to purchase up to an additional 43,000 ADSs to cover over-allotments, if any. &nbsp;
The Company intends to use the proceeds for resource and exploration field programs, including additional drilling and exploration, feasibility studies, and general working capital.

NVAAF

Reported Earlier, Nova Minerals Raised $2.15M Via Secondary Offering Of 0.43M ADS At $5/ADS

T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) ("T-Mobile") announced today that T-Mobile USA, Inc., its direct wholly-owned subsidiary ("T-Mobile USA" or the "Issuer"), has agreed to sell $700,000,000 aggregate principal amount of its 4.200% Senior Notes due 2029 (the "2029 Notes"), $900,000,000 aggregate principal amount of its 4.700% Senior Notes due 2035 (the "2035 Notes") and $900,000,000 aggregate principal amount of its 5.250% Senior Notes due 2055 (the "2055 Notes," and collectively with the 2029 Notes and the 2035 Notes, the "notes") in a registered public offering.
The offering of the notes is scheduled to close on September 26, 2024, subject to satisfaction of customary closing conditions. T-Mobile USA intends to use the net proceeds from the offering for general corporate purposes, which may include among other things, share repurchases, any dividends declared by T-Mobile's Board of Directors and refinancing of existing indebtedness on an ongoing basis.

TMUS

Reported Earlier, T-Mobile To Raise $2.5B Via Senior Notes Offering

New Mountain Finance Corporation (the "Company," "we," "us" or "our") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) today announced that it has priced an underwritten public offering of $300 million in aggregate principal amount of 6.200% unsecured notes due 2027 (the "Notes").
The Notes will mature on October 15, 2027, and may be redeemed in whole or in part at the Company's option at any time prior to October 15, 2027, at par plus a "make-whole" premium plus accrued interest. The Notes will bear interest at a rate of 6.200% per year payable semi-annually on April 15 and October 15 of each year, beginning April 15, 2025.
The offering is expected to close on September 26, 2024, subject to the satisfaction of customary closing conditions.

NMFC

Reported Earlier, New Mountain Finance Raised $300M Via Secondary Offering Of Unsecured Notes Due 2027

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lnw.com%2F&amp;esheet=54126322&amp;newsitemid=20240923020206&amp;lan=en-US&amp;anchor=Light+%26amp%3B+Wonder%2C+Inc.&amp;index=1&amp;md5=b86e6598104a68d63d8555273b511202">Light &amp; Wonder, Inc.</a> (NASDAQ and ASX: LNW) (together with its subsidiaries "Light &amp; Wonder," "L&amp;W" or the "Company") today received an order from the U.S. District Court for the District of Nevada granting Aristocrat a preliminary injunction relating to L&amp;W's Dragon Train game. We respectfully disagree with the judge's decision and will promptly file an appeal. We will continue to vigorously defend against Aristocrat's claims, including presenting our defenses to a jury at a trial.
Light &amp; Wonder reaffirms its 2025 $1.4 billion Targeted Consolidated AEBITDA(1). We expect continued strong growth across all our businesses. The Company is moving forward on a number of key initiatives to mitigate the immediate impact and any continuing business disruption from today's order. Our pre-ruling estimate of 2025 Consolidated AEBITDA(1) for Dragon Train was less than 5%(2) of the $1.4 billion.
We have a diversified portfolio of successful game franchises that are driving our strong performance and growth, of which Dragon Train is only one. Increased investment in our R&amp;D engine has and continues to deliver innovative, engaging content that gives us a continuing competitive advantage not tied to any one game or franchise.
Light &amp; Wonder has the #1 share(3) and #1 performance position overall for top new sold games and has the top performing game in all 5 for sale categories in North America(4). Additionally, Light &amp; Wonder has 8 of the top 25 premium leased and wide-area progressive parent theme games(4). Our chart-topping game performance continues to be underpinned by our franchises such as ULTIMATE FIRE LINK&#x2122;, INVADERS, our hit Asian-themed games 88 FORTUNES&#xAE; and DANCING DRUMS&#xAE;, stepper favorites QUICK HIT&#x2122; and TRIPLE BLAZING 7s&#x2122;, and Huff N' Puff&#xAE;, where we recently launched a new game extension Huff N' Puff Money Mansion&#xAE; as a leased game. Our market-leading game franchises will continue to drive our Company's strong growth over the long term. We are also already working on new iterations of the Dragon Train franchise consistent with the terms of the Court's ruling.
"We have the best game design talent in the industry, and they are creating great games across all our channels," said Matt Wilson, President and CEO of Light &amp; Wonder. "We are excited about the new games we will be featuring at the Global Gaming Expo in October. We expect our strong growth trajectory to continue, notwithstanding this decision. We have built an amazing business and a solid financial foundation over the last several years with great teams driving our success and are highly confident in our future of continuing innovation and ability to achieve our stated 2025 $1.4 billion Targeted Consolidated AEBITDA(1)."
Our robust capital management strategy remains unchanged. We continue to allocate capital where we can achieve the best shareholder returns, including share repurchases pursuant to our recently approved $1 billion program along with value accretive organic and inorganic investments.

Guidance

Legal

Reported Earlier, Light & Wonder Confirms $1.4B 2025 Consolidated AEBITDA After Court Ruling On Dragon Train Game

BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants ("Pre-funded Warrants") in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions. &nbsp;

BIVI

Reported Earlier, BioVie Raised $3M VIa Secondary Stock Offering Of 1.96M Shares At $1.53/Share

InvenTrust Properties Corp. ("InvenTrust" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) today announced it has priced an underwritten registered public offering of 8,000,000 shares of its common stock at a price to the public of $28.00 per share for total gross proceeds of $224.0 million. As part of the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of the Company's common stock at the public offering price, less the underwriting discount. The offering is expected to close on September 25, 2024 subject to customary closing conditions.
J.P. Morgan, BofA Securities, and Wells Fargo Securities are acting as joint-book-running managers for the public offering. Jefferies and KeyBanc Capital Markets are acting as additional bookrunners for the public offering. BTIG and Fifth Third Securities are acting as co-managers for the public offering.
The Company intends to use the net proceeds for general corporate purposes, including, but not limited to, funding the acquisition of additional properties, repayment of short-term and long-term indebtedness (including mortgage loans, including a $72.5 million loan with Bank of America, N.A, and amounts outstanding from time to time under the Company's revolving credit facility) and providing for working capital.

Reported Earlier, InvenTrust Properties Raised $224M Via Upsized Secondary Stock Offering Of 8M Shares (Prior $6.5M Shares) At $28/Share

Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) ("HEI" or the "Company") today announced that it has priced its previously announced public offering of 54,054,054 shares of its common stock at a price of $9.25 per share. The offering is expected to close on September 25, 2024, subject to customary closing conditions.
The Company has granted the underwriters of the offering an option to purchase up to an additional 8,108,108 shares of common stock at the public offering price less underwriting discounts and commissions.
HEI intends to use the net proceeds from the offering to fund its contribution to the expected Maui wildfire tort litigation settlement and for general corporate purposes.

Hawaiian Electric Industries Raised $500M Via Secondary Stock Offering Of 54M Shares At $9.25/Share

<a href="https://www.globenewswire.com/Tracker?data=QOxRsnrI4lIcPvAJOHMkqpD2ZCcXLqncOnt8jZtYl5Orntqk98Ug6cXUt26iWYSQ">UCB</a> (Euronext Brussels: UCB) and <a href="https://www.globenewswire.com/Tracker?data=dQmAuZ_6afdr57GCMIz_bBuykaXWwgeC4T9F0-q_hAYdmPT_oUGMDy50CId7wM1j4bYykSMNSRmZ3zuqKQjiUA==">Biogen Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) today announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus (SLE). Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
The safety profile of dapirolizumab pegol was generally consistent with previous studies and with that expected in study participants with systemic lupus erythematosus receiving an immunomodulator.
"These positive results with dapirolizumab pegol represent encouraging progress in the development of medicines that can improve the lives of those living with lupus, an area that remains one of high unmet medical need and where women are disproportionately affected," said Fiona du Monceau, Head of Patient Evidence at UCB. "We have confidence in the unique mode of action of dapirolizumab pegol which targets multiple inflammatory pathways involved in the pathogenesis of SLE. As we pursue the next steps in the clinical development of this potentially differentiated treatment, we extend our appreciation to the patients, study investigators and the clinical community for their ongoing support and participation in this important research."
Based on the successful outcome of the PHOENYCS GO study, UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
"Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE disease burden. These results demonstrate that dapirolizumab pegol has the promise to provide meaningful benefit in this serious, chronic, and often devastating disease," said Diana Gallagher, MD, Head of AD, MS and Immunology Development Units at Biogen. "We are committed to delivering new treatment options for this autoimmune disease and believe the overall efficacy and safety seen in PHOENYCS GO support further development of dapirolizumab pegol in SLE."
PHOENYCS GO (n= 321) is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of dapirolizumab pegol as an add on therapy to standard of care compared to placebo with standard of care. The primary outcome measure was improvement of moderate-to-severe disease activity at Week 48 using BICLA, an established, composite primary efficacy endpoint for measurement of clinical disease activity based on patient medical history, clinical examination and laboratory tests.
Detailed results from the PHOENYCS GO study will be presented at an upcoming medical congress.

BIIB

UCB And Biogen Report Results In Phase 3 Lupus Drug Trial

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Icecure Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/iccm-stock-quote/">ICCM</a>) just reported results for the second quarter of 2024.<ul><li>Icecure Medical reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -7 cents.</li><li>The company reported revenue of $1.01 million.</li><li>This was 8.71% better than the analyst estimate for revenue of $930,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/iccm-stock-earnings-icecure-medical-for-q2-of-2024/">ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024

IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Icecure Medical (ICCM – Research Report) today and set a price target of $2.50. Yi Chen ...

Icecure Medical: A Strong Buy on Robust Financials and Regulatory Advancements

Maxim Group analyst Anthony Vendetti has reiterated their bullish stance on ICCM stock, giving a Buy rating today. Anthony Vendetti has given his B...

Icecure Medical Poised for Growth: A Comprehensive Buy Recommendation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Icecure Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/iccm-stock-quote/">ICCM</a>) just reported results for the second quarter of 2024.<ul><li>Icecure Medical reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -7 cents.</li><li>The company reported revenue of $1.01 million.</li><li>This was 8.71% better than the analyst estimate for revenue of $930,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/iccm-stock-earnings-icecure-medical-for-q2-of-2024/">ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Icecure Medical (ICCM) has released an update. IceCure Medical Ltd. has been granted a new U.S. patent for its innovative cryogenic pump technology...

IceCure Medical Strengthens Patent Portfolio

Icecure Medical (ICCM) has released an update. IceCure Medical has announced an FDA Advisory Panel meeting scheduled for November 7, 2024, to discu...

IceCure's ProSense® Awaits FDA Panel Review

FDA AdComm to discuss IceCure's ProSense on Nov. 7

Icecure Medical (ICCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wa...

IceCure Medical's ProSense Positioned for Market Success Following FDA Panel Meeting, Analyst Maintains Buy Rating

Icecure Medical (ICCM) has released an update. IceCure Medical's ProSense cryoablation technology, which destroys tumors by freezing, demonstrated ...

IceCure's ProSense Shows High Success in Tumor Treatment

Screenshot 2024-04-12 at 5.32.25 PM

Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery

Small Cap

Press Releases

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Icecure Medical

Icecure Medical (ICCM) Forecast

Icecure Medical (NASDAQ:ICCM) Stock, Quote.Headers.trade-ideas